Biofluid biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behavior disorder
臧雅杰 1毛薇 1武昱
扫码查看
点击上方二维码区域，可以放大扫码查看
作者信息
1. 首都医科大学宣武医院神经内科，北京 100053
折叠
摘要
特发性快动眼睡眠行为障碍（iRBD）被认为是α-突触核蛋白病的前驱期，为探索α-突触核蛋白病的发病机制和早期干预提供了重要窗口。既往很多在iRBD人群进行预测疾病转化的标志物的相关研究，主要集中在临床、体液、影像领域，其中体液标志物因其对病理变化的直接反应以及良好的可及性成为颇有前景的生物标志物，这些研究涉及不同致病机制相关的物质，结果一致性较差。本文对既往iRBD患者体液标志物研究做一综述，以期为后续研究提供参考。 Isolated rapid-eye-movement sleep behavior disorder (iRBD) is considered to be a prodromal stage of α-synucleinopathies, providing an important period for investigating biomarkers of conversion risk and potentially disease-modifying intervention. Many previous studies investigating biomarkers in patients with iRBD have focused on different domains including clinical, body fluid and imaging. Due to their direct response to the pathological changes of brain and advantaged accessibility, body fluid markers have become promising potential biomarkers. These studies have involved different molecules related to different pathogenic mechanisms with poor consistency of results. In this paper, a review of previous work on body fluid markers in patients with iRBD is presented.
Abstract
Isolated rapid-eye-movement sleep behavior disorder (iRBD) is considered to be a prodromal stage of α-synucleinopathies, providing an important period for investigating biomarkers of conversion risk and potentially disease-modifying intervention. Many previous studies investigating biomarkers in patients with iRBD have focused on different domains including clinical, body fluid and imaging. Due to their direct response to the pathological changes of brain and advantaged accessibility, body fluid markers have become promising potential biomarkers. These studies have involved different molecules related to different pathogenic mechanisms with poor consistency of results. In this paper, a review of previous work on body fluid markers in patients with iRBD is presented.
万方数据